Page last updated: 2024-10-28

idebenone and Aging

idebenone has been researched along with Aging in 8 studies

Aging: The gradual irreversible changes in structure and function of an organism that occur as a result of the passage of time.

Research Excerpts

ExcerptRelevanceReference
"We report that α-tocotrienol quinone (ATQ3) is a metabolite of α-tocotrienol, and that ATQ3 is a potent cellular protectant against oxidative stress and aging."7.77α-Tocotrienol quinone modulates oxidative stress response and the biochemistry of aging. ( Amagata, A; Barnes, A; Enns, GM; Hinman, A; Jankowski, O; Kheifets, V; Komatsuzaki, R; Lee, E; Miller, G; Mollard, P; Murase, K; Sadun, AA; Shrader, WD; Thoolen, M; Wesson, K, 2011)
"We report that α-tocotrienol quinone (ATQ3) is a metabolite of α-tocotrienol, and that ATQ3 is a potent cellular protectant against oxidative stress and aging."3.77α-Tocotrienol quinone modulates oxidative stress response and the biochemistry of aging. ( Amagata, A; Barnes, A; Enns, GM; Hinman, A; Jankowski, O; Kheifets, V; Komatsuzaki, R; Lee, E; Miller, G; Mollard, P; Murase, K; Sadun, AA; Shrader, WD; Thoolen, M; Wesson, K, 2011)
"Idebenone is a benzoquinone compound which has been investigated in elderly patients with dementia."2.39Idebenone. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in age-related cognitive disorders. ( Benefield, P; Gillis, JC; McTavish, D, 1994)

Research

Studies (8)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's6 (75.00)18.2507
2000's0 (0.00)29.6817
2010's2 (25.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Shrader, WD1
Amagata, A1
Barnes, A1
Enns, GM1
Hinman, A1
Jankowski, O1
Kheifets, V1
Komatsuzaki, R1
Lee, E1
Mollard, P1
Murase, K1
Sadun, AA1
Thoolen, M1
Wesson, K1
Miller, G1
García-Giménez, JL1
Gimeno, A1
Gonzalez-Cabo, P1
Dasí, F1
Bolinches-Amorós, A1
Mollá, B1
Palau, F1
Pallardó, FV1
Nabeshima, T2
Nitta, A2
Fuji, K1
Kameyama, T1
Hasegawa, T2
Gillis, JC1
Benefield, P1
McTavish, D1
Pelleymounter, MA1
Cullen, MJ1
Curti, D1
Izzo, E1
Brambilla, L1
Facchetti, G1
Sangiovanni, G1
Brambilla, G1
Kamei, C1
Tsujimoto, S1
Tasaka, K1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Therapeutic Trial of EPI -743 In Patients With Disorders of Energy Utilization or Oxidation-Reduction[NCT01642056]Phase 1/Phase 220 participants (Actual)Interventional2012-09-01Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Newcastle Paediatric Mitochondrial Disease Scale (NPMDS) Part I-III, 14 Months

"NPMDS is a semi-quantitative clinical rating scale that evaluates the progression of mitochondrial disease in pediatric patients.~The NPMDS scale provides an assessment of the progression of mitochondrial disease. Scores from Parts I-III are added to get a value between 0 and 130, with higher scores representing more severe disease." (NCT01642056)
Timeframe: 14 months

InterventionUnits on a scale (Mean)
EPI-743, Then Placebo26
Placebo, Then EPI-74315.8

Newcastle Paediatric Mitochondrial Disease Scale (NPMDS) Part I-III, 6 Months

"NPMDS is a semi-quantitative clinical rating scale that evaluates the progression of mitochondrial disease in pediatric patients.~The NPMDS scale provides an assessment of the progression of mitochondrial disease. Scores from Parts I-III are added to get a value between 0 and 130, with higher scores representing more severe disease." (NCT01642056)
Timeframe: 6 months

InterventionUnits on a scale (Mean)
EPI-743, Then Placebo27.1
Placebo, Then EPI-74320.2

Newcastle Paediatric Mitochondrial Disease Scale (NPMDS) Part I-III, Baseline

"NPMDS is a semi-quantitative clinical rating scale that evaluates the progression of mitochondrial disease in pediatric patients.~The NPMDS scale provides an assessment of the progression of mitochondrial disease. Scores from Parts I-III are added to get a value between 0 and 130, with higher scores representing more severe disease." (NCT01642056)
Timeframe: Baseline - Day 0

InterventionUnits on a scale (Mean)
EPI-743, Then Placebo23.9
Placebo, Then EPI-74320.4

Newcastle Paediatric Mitochondrial Disease Scale (NPMDS) Part I-III, Post Washout

"NPMDS is a semi-quantitative clinical rating scale that evaluates the progression of mitochondrial disease in pediatric patients.~The NPMDS scale provides an assessment of the progression of mitochondrial disease. Scores from Parts I-III are added to get a value between 0 and 130, with higher scores representing more severe disease." (NCT01642056)
Timeframe: 8 month - Post washout

InterventionUnits on a scale (Mean)
EPI-743, Then Placebo27.1
Placebo, Then EPI-74318.3

Reviews

1 review available for idebenone and Aging

ArticleYear
Idebenone. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in age-related cognitive disorders.
    Drugs & aging, 1994, Volume: 5, Issue:2

    Topics: Administration, Oral; Aging; Benzoquinones; Cognition Disorders; Drug Administration Schedule; Human

1994

Other Studies

7 other studies available for idebenone and Aging

ArticleYear
α-Tocotrienol quinone modulates oxidative stress response and the biochemistry of aging.
    Bioorganic & medicinal chemistry letters, 2011, Jun-15, Volume: 21, Issue:12

    Topics: Aging; Animals; Antioxidants; Benzoquinones; Cells, Cultured; Dogs; Dose-Response Relationship, Drug

2011
Differential expression of PGC-1α and metabolic sensors suggest age-dependent induction of mitochondrial biogenesis in Friedreich ataxia fibroblasts.
    PloS one, 2011, Volume: 6, Issue:6

    Topics: Adenosine Triphosphate; Adolescent; Adult; Aging; Alleles; AMP-Activated Protein Kinases; Antioxidan

2011
Oral administration of NGF synthesis stimulators recovers reduced brain NGF content in aged rats and cognitive dysfunction in basal-forebrain-lesioned rats.
    Gerontology, 1994, Volume: 40 Suppl 2

    Topics: Administration, Oral; Aging; Analysis of Variance; Animals; Benzoquinones; Brain; Choline O-Acetyltr

1994
Effects of idebenone on information processing in aged Long-Evans rats.
    Pharmacology, biochemistry, and behavior, 1993, Volume: 46, Issue:2

    Topics: Aging; Animals; Anxiety; Attention; Benzoquinones; Cognition; Environment; Habituation, Psychophysio

1993
Oral administration of idebenone, a stimulator of NGF synthesis, recovers reduced NGF content in aged rat brain.
    Neuroscience letters, 1993, Dec-12, Volume: 163, Issue:2

    Topics: Administration, Oral; Aging; Animals; Benzoquinones; Brain; Choline O-Acetyltransferase; Frontal Lob

1993
Effect of a ubiquinone-like molecule on oxidative energy metabolism in rat cortical synaptosomes at different ages.
    Neurochemical research, 1995, Volume: 20, Issue:9

    Topics: Adenosine Triphosphate; Aging; Animals; Benzoquinones; Cerebral Cortex; Energy Metabolism; Enzyme Ac

1995
Effects of cholinergic drugs and cerebral metabolic activators on memory impairment in old rats.
    Journal of pharmacobio-dynamics, 1990, Volume: 13, Issue:12

    Topics: Acetylcholine; Aging; Animals; Benzoquinones; Brain; Central Nervous System Agents; gamma-Aminobutyr

1990